What is Jesduvroq?
Jesduvroq is a brand name for the medicine sotrovimab (an antibody medicine). It’s used for the treatment of COVID-19 in certain patients, based on guidance and approval details for the relevant country or regulator.
What does it treat, and who is it for?
Jesduvroq/sotrovimab is aimed at people with COVID-19 who are at risk of progressing to severe disease, under the specific eligibility rules set by regulators and clinicians.
How does Jesduvroq work?
Sotrovimab is a monoclonal antibody. It binds to a target on the SARS‑CoV‑2 virus, helping block infection and reduce the risk of the illness worsening.
Is it a tablet, injection, or infusion?
Jesduvroq is given as an injected/infused antibody treatment (the exact administration method can depend on local prescribing information).
Is it still available, and has anything replaced it?
Availability can vary by country and by updated clinical guidance as the virus and treatment recommendations change. If you tell me your country (or where you saw the name), I can narrow down the exact status and approved use.
What are the main side effects people ask about?
Commonly reported concerns for monoclonal antibody COVID-19 treatments include infusion or injection reactions (such as rash, fever, or allergy-like symptoms). Your clinician’s instructions and the local product label are the best source for the full side-effect list.
If you share where you saw “Jesduvroq” (a prescription, a pharmacy listing, or a country/regulator), I can confirm the exact product details tied to that listing.